CAPRICOR THERAPEUTICS INC. - COMMON STOCK

Capricor Therapeutics Announces First Subjects Dosed in Phase 1 Clinical Trial of Novel Exosome-Based Vaccine

18 Aug 2025 06:00:00 By Nasdaq GlobeNewswire

Capricor Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

11 Aug 2025 13:05:00 By Nasdaq GlobeNewswire

Capricor Therapeutics Announces Type A Meeting Scheduled with U.S. FDA

08 Aug 2025 05:30:00 By Nasdaq GlobeNewswire

Capricor Therapeutics to Present Second Quarter 2025 Financial Results and Recent Corporate Update on August 13

06 Aug 2025 06:00:00 By Nasdaq GlobeNewswire

Capricor Therapeutics and Parent Project Muscular Dystrophy to Host Webinar to Review Latest Developments in the Deramiocel Program for the Treatment of Duchenne Muscular Dystrophy

28 Jul 2025 06:00:00 By Nasdaq GlobeNewswire

Capricor Therapeutics Provides Regulatory Update on Deramiocel BLA for Duchenne Muscular Dystrophy

11 Jul 2025 03:30:00 By Nasdaq GlobeNewswire

Capricor Therapeutics Provides Regulatory Update on Deramiocel BLA for Duchenne Muscular Dystrophy

24 Jun 2025 06:00:00 By Nasdaq GlobeNewswire

Capricor Therapeutics Announces Positive 4-Year Data from HOPE-2 Open-Label Extension Study of Deramiocel in Duchenne Muscular Dystrophy

20 Jun 2025 06:25:00 By Nasdaq GlobeNewswire

Capricor Therapeutics Announces Orphan Drug Designation for Becker Muscular Dystrophy and Regulatory Progress for Duchenne Muscular Dystrophy Program

17 Jun 2025 06:00:00 By Nasdaq GlobeNewswire

Capricor Therapeutics Announces Key Regulatory Updates for its Duchenne Muscular Dystrophy Program

11 Jun 2025 06:25:00 By Nasdaq GlobeNewswire

Capricor Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

13 May 2025 13:05:00 By Nasdaq GlobeNewswire

Capricor Therapeutics Appoints Michael Binks, M.D. as Chief Medical Officer

13 May 2025 06:00:01 By Nasdaq GlobeNewswire

Capricor Therapeutics to Present First Quarter 2025 Financial Results and Recent Corporate Update on May 13

06 May 2025 06:15:00 By Nasdaq GlobeNewswire

Capricor Therapeutics Announces Completion of Mid-Cycle Review Meeting with FDA on Deramiocel for the Treatment of Duchenne Muscular Dystrophy Cardiomyopathy

05 May 2025 05:00:01 By Nasdaq GlobeNewswire

Capricor Therapeutics to Present at the 2025 Piper Sandler Virtual Cardio Day

01 Apr 2025 06:00:00 By Nasdaq GlobeNewswire

Capricor Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

19 Mar 2025 13:05:00 By Nasdaq GlobeNewswire

Capricor Therapeutics Announces Positive Data Demonstrating Long-Term Efficacy of Deramiocel for the Treatment of Duchenne Muscular Dystrophy

17 Mar 2025 06:25:00 By Nasdaq GlobeNewswire

Capricor Therapeutics to Present Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Update on March 19

11 Mar 2025 06:00:00 By Nasdaq GlobeNewswire

Capricor Therapeutics to Present at Leerink’s Global Healthcare Conference 2025

07 Mar 2025 06:25:00 By Nasdaq GlobeNewswire

Capricor Therapeutics Announces FDA Acceptance and Priority Review of its Biologics License Application for Deramiocel to Treat Duchenne Muscular Dystrophy

04 Mar 2025 04:00:00 By Nasdaq GlobeNewswire